“Twelve weeks ago, these projects were literally just ideas,” said Rana Quraishi, PhD, director of new ventures in the Office of Research and Development at the University of Maryland, Baltimore (UMB). Quraishi was welcoming students, intellectual property experts, and scientists to the final meeting of UMB’s first-ever course in developing and pitching a biotechnology business concept, called CIPP 980.
Longtime San Franciscans may remember the Mission Bay neighborhood, located on the southern end of the city, as the home to one of the Southern Pacific Railroad Company’s railyards. Trains ran in and out of the railyard for nearly 100 years until the 1990s.
The National Institute of Standards and Technology (NIST) released a federal funding opportunity (FFO) to establish and sustain up to eight Regional Alliances and Multistakeholder Partnerships to Stimulate (RAMPS) Cybersecurity Education and Workforce Development. Through this announcement, NIST will commit up to $1.6 million for state or regional consortiums that identify cybersecurity workforce development pathways that address local workforce needs. Although lead organizations must be a nonprofit or institution of higher education, NIST encourages public-private partnerships with industry and local governments. Proposals are due July 12, 2016.
Novavax Inc. has won a potentially lucrative fast-track designation from the U.S. Food and Drug Administration for one of its lead vaccine candidates to protect older patients against a respiratory virus known as RSV.
The Association of University Research Parks is proud to present the 2016 Awards of Excellence in research and science park development and practice.
AURP will honor industry leaders at the 2016 International Conference in Oklahoma City, Oklahoma.
Please submit nominees by Friday, July 15, 2016.
The National Council of Entrepreneurial Tech Transfer (NCET2) will hold its inaugural University Startups Demo Day (USDD) at the National Press Club and Congress in Washington, DC on September 20, 2016.
The USDD provides an unprecedented opportunity for corporate open innovation and venturing groups, VCs, and angels to discover, review, partner with, and fund university startups. At the same time, it raises awareness in Congress of the pivotal role that universities play in the formation of high potential startups, the creation of high value jobs across the country, and overall national competitiveness.
The USDD will showcase thirty-five (35) of the best university startups in specific technology areas. Selected by their universities, and scored by corporates, angels, and VCs, the top scoring university startups will be invited to present at the National Press Club in the first part of the day. During the second part of the day, the companies will meet and have photo ops with their senators and representatives at Congress.
The National Science Foundation’s I-Corps initiative is heavily influenced by the lean start-up methodology, which calls for rapid iteration of value propositions and customer segments based on formal and extensive interviews with the industry stakeholders of a technology or service. While this methodology has proven to be very successful overall, many universities have reported difficulty engaging faculty in the process because of the six-week commitment to the program.
Women who get a prosthetic foot after losing a leg to disease or injury have limited shoe options, but an invention by five Johns Hopkins University students may change that. The university announced Wednesday that the “Prominence” could be the first non-custom prosthetic foot to adapt to high heels up to 4 inches high.
Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced it has signed an exclusive distribution agreement with Roche for the multi-country commercialization of Senseonics’ Eversense® Continuous Glucose Monitoring System.
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer. The published study details research in an in vivo model that showed the company’s drug candidate, GMI-1271, a novel E-selectin antagonist, inhibits breast cancer metastasis.
